[China BD 2025] DualityBio and Avenzo enters a 1.2 billion USD license for EGFR/HER3 BsADC DB-1418 (AVZO-1418)

Announced Date: 2025-01-07 (January 7, 2025)

Asset Name: DB-1418 (AVZO-1418)

Licensor (Seller): Duality Biotherapeutics (China)

Licensee (Buyer): Avenzo Therapeutics (US)

.

Asset Modality: ADC (antibody drug conjugate) , topoisomerase-1 inhibitor-based

Asset Target: targeting both EGFR and HER3

Potential Indication:  multiple solid tumor 

Current Stage: preclinical

.

Scope of Authority:  

Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418 globally (excluding Greater China).

.

Deal Detail:

DualityBio will receive

Upfront payment of $50 million,

Development, regulatory and commercial milestone payments up to approximately $1.15 billion.

Tiered royalties on sales in Avenzo’s territory.

.

Link:

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate | Avenzo Therapeutics (avenzotx.com)

.

Note:

Chinese Name of Duality Biotherapeutics, 映恩生物